Locally Advanced or Metastatic Non-Small Cell Lung Cancer Clinical Trials

25 clinical trials for Locally Advanced or Metastatic Non-Small Cell Lung Cancer across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AST2303 Tablets (ABK3376 Tablets) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer — RECRUITING · PHASE1
• A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer — RECRUITING · PHASE2
• Study of PF-07248144 in Advanced or Metastatic Solid Tumors — RECRUITING · PHASE2
• Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC — RECRUITING · PHASE1
• Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects — RECRUITING · PHASE2
• A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors — RECRUITING · PHASE1
• A randomised Phase 3 Trial of ALIMTA and Cisplatin versus GEMZAR and Cisplatin in Patients with locally advanced or metastatic Non-Small-Cell Lung Cancer — COMPLETED · PHASE3
• A multinational, randomized, double blind, controlled phase II trial of ombrabulin with taxane and platinum combination administered every three weeks, in first line treatment of patients with metastatic Non-Small-Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer — COMPLETED · PHASE2
• A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) — TERMINATED · PHASE3
• A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations — ACTIVE_NOT_RECRUITING · PHASE3
• A study of STX-721/PFL-721 in participants with non-small cell lung cancer with certain mutations — TERMINATED · PHASE2
• A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure — TERMINATED · PHASE3
• AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER — TERMINATED · PHASE3
• An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations — TERMINATED · PHASE2
• A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. — NOT_YET_RECRUITING · PHASE2
• A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC) — OTHER · PHASE2
• Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer — OTHER · PHASE3
• A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC) — OTHER · PHASE2
• Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer — OTHER
• Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer — OTHER · PHASE2
• Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer — OTHER · PHASE1
• Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients — TERMINATED · PHASE1
• Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer — COMPLETED · PHASE2

Refine this search